Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of ARTS-011 in Chinese Healthy Volunteers
NCT06260527Phase 1Completed
- Sponsor
- Allorion Therapeutics
- Start
- Aug 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ARTS-011 in psoriasis (3 cohorts), sponsored by Allorion Therapeutics. Primary endpoints: Incidence of Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs at Day 15, Number of Adverse Events (AEs) according to severity at Day 15 and 4 more. Started Aug 2023; status: completed.
02
Drugs
ARTS-011
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT06260527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06260527.